Compare Globus Medical Inc. Class A Common Stock (GMED) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Teucrium Soybean Fund — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Teucrium Soybean Fund trades at $27.2 (market cap $43.28M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 236.8× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Teucrium Soybean Fund for 25 Days on average.
| GMED | SOYB | |
|---|---|---|
Market Cap | $10.25B | $43.28M |
Volume | 1,108,124 | 28,719 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $96.82 | $28.14 |
52-Week Low | $58.33 | $21.59 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SOYB trades at $27.33, down 0.51% today, with a bullish technical signal driven by moving averages. The stock is consolidating near key support at $27, with neutral oscillators indicating limited momentum. Recent news highlights potential catalysts from U.S.-China trade talks, which could boost soybean demand.
The outlook hinges on trade developments and commodity price trends, offering upside if diplomatic progress materializes. Risks include geopolitical tensions and commodity market volatility. Analyst sentiment appears cautiously optimistic, but fundamental data remains sparse for detailed assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
